Supernus Pharmaceuticals (NASDAQ:SUPN) Downgraded to Hold Rating by Wall Street Zen
Wall Street Zen cut shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a hold rating in a report released on Saturday morning. Separately, Cantor Fitzgerald reiterated a “neutral” rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. Check Out […]
Wall Street Zen cut shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a hold rating in a report released on Saturday morning. Separately, Cantor Fitzgerald reiterated a “neutral” rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. Check Out […]
